Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Deals Of The Week: Abbott/Reata, Bristol-Myers Squibb/Simcere, Intarcia/Quintiles

Executive Summary

Abbott sends another financial record tumbling as it pays an all-time high $400 million upfront for preclinical AIM compounds from Reata.


Related Content

Abbott Pays $400 Million Upfront For Reata’s Preclinical AIM Programs
Pharmacyclic’s Co-Development Pact With Janssen Carries Largest Single-Asset Upfront Payment Of 2011
Simcere Will Co-Develop Cancer Drugs With BMS; A New R&D Model Between China And U.S.?
Abbott Pays $450MM Up-Front For Rights To Reata's CKD Drug
Celgene/Agios Team Up In Long-Term Cancer Metabolism Pact


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts